Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, and step therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act; H.R.2630, Safe Step Act.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
Issues related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Issues related to orphan drug tax credit; H.R.5539/S.3131, ORPHAN Cures Act.
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP and supply chain.
Duration: October 1, 2012
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Trade (Domestic & Foreign)
Spending: about $1,800,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), U.S. Senate,, Substance Abuse & Mental Health Services Administration (SAMHSA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John Green Dep Chief of Staff/Leg Aide, Senator Trent Lott
Stewart Hall Legislative Director, Senator Richard Shelby
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Policy Advisor, Sen. Cochran; Special Asst, National Economic Council; Prof. Staff, Senate Approps Comm; LA, Sen. Cochran; LA/Subcomm Staff Dir, House Ag Comm; LA, Rep. Parker
Matt Wise LegDirector/LegAide, Rep.Mary Fallin; LC, Sen.Conrad Burns
Steve Tilton HCRPolCoor/SenPolAdvr:ENG/CommBilirakis
Todd M. Weiss PolAdv,Hutchinson;LA/LD,Santorum;Staff,IntlRel
Anne W. Brady Deputy Chief of Staff, Rep. Mark Schauer
Jake Perry Legislative Aide, Sen. Harry Reid
Elizabeth Hart CoS,Cong. John Carney;CoS/Dep CoS/LD,Cong. Melissa Bean;Sr. LA,Cong. Baron Hill
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Katherine Dapper Staff Assistant, Senator Patty Murray
Jason Gleason Chief of Staff/ Legislative Director, Rep. John Sarbanes; Legislative Director/ Legislative Asst/ Legislative Correspondent/ Staff Asst, Sen. Paul Sarbanes
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Ivelisse Porroa-Garcia Policy Director, Congressional Hispanic Caucus (CHC); Legislative Assistant, Rep. Raul Ruiz; Staff Assistant, Sen. Barbara Boxer
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
Mathew Lapinski n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301572907.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, and step therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act; H.R.2630, Safe Step Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Issues related to orphan drug tax credit; H.R.5539/S.3131, ORPHAN Cures Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 20.
Original Filing: 301533793.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, international pharmaceutical supply chain, plasma therapy, and step therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act; H.R.2630, Safe Step Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511128.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, international pharmaceutical supply chain, and plasma therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act;
H.R.5378, Lower Costs, More Transparency Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on July 19, 2023.
Original Filing: 301484467.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, international pharmaceutical supply chain, and plasma therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301459932.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, international pharmaceutical supply chain, and plasma therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
H.R.830, HELP Copays Act;
S.127, Pharmacy Benefit Manager Transparency Act of 2023;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435471.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, home infusion, plasma therapy, PDUFA Reauthorization, and clinical trial diversity; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 19, 2022.
Original Filing: 301411851.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, plasma therapy, PDUFA Reauthorization, and clinical trial diversity; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301388481.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, plasma therapy, and PDUFA Reauthorization; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on April 19, 2022.
Original Filing: 301360031.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, plasma therapy, and PDUFA Reauthorization; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 19, 2022.
Original Filing: 301326929.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, and plasma therapy.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to the Budget Reconciliation Process (S.Con.Res.14, H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 19, 2021.
Original Filing: 301304984.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, and plasma therapy.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Tax issues related to the Budget Reconciliation Process (S.Con.Res.14, H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on July 18, 2021.
Original Filing: 301279151.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, and plasma therapy.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on April 19, 2021.
Original Filing: 301256482.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, home infusion, and plasma therapy.
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301237457.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
H.R.7839, Continuing Access to In-Home IVIG Act.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
H.R.7783, Plasma Donation Awareness Act of 2020; S.4179, Plasma Donation Awareness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; S.1895, Lower Health Care Costs Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Oct. 17, 2020.
Original Filing: 301212598.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
H.R.7839, Continuing Access to In-Home IVIG Act.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to federal health programs and prescription drugs;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on July 18, 2020.
Original Filing: 301193313.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
Implementation of 21st Century Cures Act (P.L.114-255).
Reauthorization of BARDA; Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6800, The Heroes Act.
H.R.1425, State Health Care Premium Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123).
H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on April 18, 2020.
Original Filing: 301171958.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, and the international pharmaceutical supply chain.
Implementation of 21st Century Cures Act (P.L.114-255).
Reauthorization of BARDA; Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Education around COVID-19 therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121439.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
TRICARE pharmacy issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020 (P.L.116-92).
Reauthorization of BARDA; Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Oct. 18, 2019.
Original Filing: 301071803.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
TRICARE pharmacy issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
Reauthorization of BARDA; Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301052877.xml
Lobbying Issues
Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
TRICARE pharmacy issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
Reauthorization of BARDA; H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on April 21, 2019.
Original Filing: 301032806.xml
Lobbying Issues
Issues related to depression, mental health, drug pricing, opioid abuse, and direct-to-consumer (DTC) advertising.
Implementation of 21st Century Cures Act (P.L.114-255).
TRICARE pharmacy issues in National Defense Authorization Act for Fiscal Year 2020.
Reauthorization of BARDA; H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6);
FY 2020 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Jan. 19, 2019.
Original Filing: 301010578.xml
Lobbying Issues
Issues related to depression, mental health, drug pricing, opioid abuse, and direct-to-consumer (DTC) advertising.
Implementation of P.L.114-255, 21st Century Cures Act.
TRICARE pharmacy issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232).
Reauthorization of BARDA; S.2852/H.R.6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
H.R.2077, Restoring the Patient's Voice Act of 2017.
H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019.
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990676.xml
Lobbying Issues
Issues related to depression, mental health, drug pricing, opioid abuse, and direct-to-consumer (DTC) advertising.
Implementation of P.L.114-255, 21st Century Cures Act.
Implementation of P.L.115-176, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017.
TRICARE pharmacy issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232).
Reauthorization of BARDA; S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018/H.R.6378, To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act.
H.R.2077, Restoring the Patient's Voice Act of 2017.
H.R.6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid;
Part D Medicare Program (including Coverage Gap and other offsets);
Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019.
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019.
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300972546.xml
Lobbying Issues
Issues related to depression, mental health, drug pricing, and opioid abuse;
Implementation of P.L.114-255, 21st Century Cures Act;
H.R.878, Trickett Wendler Right to Try Act of 2017/S.204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (P.L.115-176);
TRICARE pharmacy issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019;
Zika funding issues in S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
H.R.2077, Restoring the Patient's Voice Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Part D Medicare Program (including Coverage Gap and other offsets).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; FDA related issues.
S.3158/House Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019; vial size issues and Zika funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300952017.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
TRICARE pharmacy issues in the FY19 National Defense Authorization Act.
P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA), issues related to Zika funding.
Issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; FDA related issues.
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; vial size issues and Zika funding.
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96); H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931518.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2810, National Defense Authorization Act for Fiscal Year 2018 (P.L.115-91), TRICARE pharmacy issues.
Issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; FDA related issues.
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; vial size issues.
H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes (P.L.115-90); H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes; H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1, Tax Cuts and Jobs Act (P.L.115-97); issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Oct. 18, 2017.
Original Filing: 300907861.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52).
H.R.2810/Senate, National Defense Authorization Act for Fiscal Year 2018; TRICARE pharmacy issues.
Issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; FDA related issues.
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; vial size issues.
H.R.3354, Make America Secure and Prosperous Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891674.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017.
Issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FDA related issues.
FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; vial size issues.
H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300868909.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FDA related issues. FY2017/FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; vial size issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $30,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847928.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144); H.R.34, 21st Century Cures Act (P.L.114-255); H.R.2646, Helping Families in Mental Health Crisis Act of 2015; S.2680, Mental Health Reform Act of 2016; S.2912, Trickett Wendler Right to Try Act of 2016; issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; FDA related issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 18, 2016.
Original Filing: 300830961.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144); H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; S.2680, Mental Health Reform Act of 2016; issues related to depression and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; FDA related issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815533.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144); S.1509/H.R.2404, Treat and Reduce Obesity Act of 2015; H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; S.2680, Mental Health Reform Act of 2016; issues related to depression, mental health and obesity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; FDA related issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on April 19, 2016.
Original Filing: 300795042.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144); S.1509/H.R.2404, Treat and Reduce Obesity Act of 2015; H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; issues related to depression, mental health and obesity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid including Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations H.Con.Res.125, Establishing the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026; FDA related issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Jan. 19, 2016.
Original Filing: 300775046.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L.113-54), the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144); S.1509/H.R.2404, Treat and Reduce Obesity Act of 2015; H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; issues related to depression, mental health and obesity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016; P.L.114-74, Bipartisan Budget Act of 2015; P.L.114-113, Consolidated Appropriations Act, 2016; FDA and other health related issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Oct. 16, 2015.
Original Filing: 300755653.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144); S.1509/H.R.2404, Treat and Reduce Obesity Act of 2015; H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016; FDA issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on July 17, 2015.
Original Filing: 300739599.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144); S.1509/H.R.2404, Treat and Reduce Obesity Act of 2015; H.R.6, 21st Century Cures Act; H.R.2646, Helping Families in Mental Health Crisis Act of 2015; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FDA issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718957.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144); Treat and Reduce Obesity Act; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FDA issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Jan. 16, 2015.
Original Filing: 300697624.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3717, Helping Families in Mental Health Crisis Act of 2013; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678922.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3717, Helping Families in Mental Health Crisis Act of 2013; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300661642.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3717, Helping Families in Mental Health Crisis Act of 2013; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on April 17, 2014.
Original Filing: 300638951.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3717, Helping Families in Mental Health Crisis Act of 2013; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; H.R.4302, Protecting Access to Medicare Act of 2014; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.3547, Continuing Appropriations Resolution, 2014 (P.L. 113-76).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Jan. 17, 2014.
Original Filing: 300618016.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; S.957, Drug Supply Chain Security Act; S.959, Pharmaceutical Quality, Security, and Accountability Act; H.R.3717, Helping Families in Mental Health Crisis Act of 2013; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.J.RES.59, Continuing Appropriations Resolution, 2014.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Oct. 18, 2013.
Original Filing: 300599276.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; S.957, Drug Supply Chain Security Act; S.959, Pharmaceutical Quality, Security, and Accountability Act; issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.J.RES.59, Continuing Appropriations Resolution, 2014.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300577680.xml
Lobbying Issues
H.R.2415/S.1184, Treat and Reduce Obesity Act of 2013.
Issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on April 18, 2013.
Original Filing: 300554663.xml
Lobbying Issues
Issues related to depression, mental health, obesity and prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Crossroads Strategies, LLC lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 19, 2013.
Original Filing: 300535967.xml
Lobbying Issues
Issues related to depression and mental health.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
Crossroads Strategies, LLC filed a lobbying registration on Nov. 7, 2012 to represent Takeda Pharmaceuticals America, Inc., effective Oct. 1, 2012.
Original Filing: 300523297.xml
Issue(s) they said they’d lobby about: Issues related to the implementation of the Patient Protection and Affordable Care Act, Prescription Drug User Fee Act reauthorization, the pharmaceutical industry, diabetes care, obesity, mental health, Medicare Part D and Medicaid. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...